Search Result

Results for "

AChE and BChE inhibitory activities

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (3) Apoptosis (1) Beta-secretase (2) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) CDK (1) Cholinesterase (ChE) (16) COX (1) Drug Intermediate (1) Glycosidase (1) JNK (1) Keap1-Nrf2 (1) Monoamine Oxidase (3) NF-κB (2) NOD-like Receptor (NLR) (1) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (2) Phosphodiesterase (PDE) (1) Reactive Oxygen Species (ROS) (1) Tau Protein (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (13)

By Targets:

Amyloid-β (3)

Apoptosis (1)

Beta-secretase (2)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

CDK (1)

Cholinesterase (ChE) (16)

COX (1)

Drug Intermediate (1)

Glycosidase (1)

JNK (1)

Keap1-Nrf2 (1)

Monoamine Oxidase (3)

NF-κB (2)

NOD-like Receptor (NLR) (1)

Nuclear Factor of activated T Cells (NFAT) (1)

p38 MAPK (2)

Phosphodiesterase (PDE) (1)

Reactive Oxygen Species (ROS) (1)

Tau Protein (1)

By Research Areas:

Cancer (3)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (13)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Targets Recommended: Macrophage migration inhibitory factor (MIF) nAChR mAChR

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-N2157

Pteryxin 1 Publications Verification (+)-Pteryxin	Cholinesterase (ChE) NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS) Nuclear Factor of activated T Cells (NFAT) p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology
Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a *BChE* inhibitor (IC₅₀=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca ²⁺-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease .

HY-N2284

Sophoflavescenol	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)	Cancer
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.

HY-W540232

4-Methoxyphenyl isothiocyanate 4-Methylphenyl ITC	Cholinesterase (ChE)	Neurological Disease
4-Methoxyphenyl isothiocyanate (4-Methylphenyl ITC) is an antioxidant, with a IC₅₀ value of 1.25 mM for scavenging DPPH radicals. ORAC testing indicates its antioxidant capacity as 11.7 mM TE (indicating that the antioxidant efficacy of this compound is equivalent to 11.7 mmol of Trolox (HY-101445, a standard antioxidant) under the same conditions), and it extends the oxidation process by approximately 9180 seconds in the Briggs–Rauscher reaction. Additionally, 4-Methoxyphenyl isothiocyanate exhibits moderate cholinesterase inhibitory activity, with an inhibition rate of 30.4% against acetylcholinesterase (AChE) and 17.9% against butyrylcholinesterase (BChE). 4-Methoxyphenyl isothiocyanate holds potential for research in the fields of antioxidation and neurological disorders .

HY-W272207

AChE/BChE-IN-31	Cholinesterase (ChE) Drug Intermediate	Neurological Disease Inflammation/Immunology
AChE/BChE-IN-31 (Compound 3c) is a cholinesterase inhibitor. AChE/BChE-IN-31 exhibits certain inhibitory activity against hAChE and eqBChE. AChE/BChE-IN-31 also possesses antioxidant properties with an IC₅₀ value of 105.04 μM against DPPH. AChE/BChE-IN-31 can be used in the research of diseases such as Alzheimer’s disease .

HY-N15710

Magnotriol B	Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
Magnotriol B is a cholinesterase inhibitor with IC₅₀ values of 12.63 nM and 14.5 nM against *AChE* and *BChE, respectively. Magnotriol B also exhibits significant NO inhibitory* activity with an IC₅₀ of 2.02 μM. Magnotriol B can be used in the research of neurodegenerative and inflammatory diseases .

HY-30139

4-Amino-2-chloropyrimidine	Biochemical Assay Reagents	Others
4-Amino-2-chloropyrimidine is a pyrimidine derivative. 4-Amino-2-chloropyrimidine is a competitive inhibitor for *AChE* (K_i = 0.18 μM) and *BChE* (K_i = 1.324 μM). 4-Amino-2-chloropyrimidine fits in the binding pocket of 4BDS. 4-Amino-2-chloropyrimidine has high inhibitory activity on GST enzyme activity (IC₅₀ = 0.037 μM, K_i = 0.047 μM) in vitro .

HY-151436

ZLMT-12	CDK Cholinesterase (ChE) Apoptosis	Cancer
ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active CDK2/9 inhibitor with IC₅₀ values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on *AChE* (IC₅₀=19.023 μM) and *BChE* (IC₅₀=2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase .

HY-N8764

Decaffeoylacteoside Decaffeoylverbascoside; Verbasoside	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease Cancer
Decaffeoylacteoside is an inhibitor of AChE/BChE/LOX with moderate activity .

HY-175658

AChE/BChE-IN-29	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
AChE/BChE-IN-29 is an *AChE/BChE* inhibitor. AChE/BChE-IN-29 exhibits balanced dual cholinesterase inhibitory activity with IC₅₀ values of 2.1 μM for Electrophorus electricus AChE (eeAChE) and 6.3 μM for equine serum butyrylcholinesterase (eqBChE). AChE/BChE-IN-29 effectively inhibits amyloid-β (Aβ₄₂) aggregation and tau protein aggregation in E. coli cell models. AChE/BChE-IN-29 can be used for the study of Alzheimer’s disease (AD) .

HY-172461

MAO-IN-6	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
MAO-IN-6 (Compound 3f) is a BBB permeable and reversible MAO-B inhibitor with an IC₅₀ of 0.09 μM. MAO-IN-6 also exhibits certain inhibitory activities against *AChE* and *BChE, with IC₅₀* values of 4.48 μM and 17.03 μM, respectively. MAO-IN-6 has low cytotoxicity and can be used in the research of Alzheimer's disease .

HY-185347

AChE-IN-114	Cholinesterase (ChE)	Neurological Disease
AChE-IN-114 is a selective *AChE* inhibitor and shows weak inhibitory activity for *BChE. AChE*-IN-114 can be used for the research of alzheimer’s disease .

HY-179121

AChE-IN-97	Cholinesterase (ChE)	Neurological Disease
AChE-IN-97 (compound 7e) is a cholinesterase inhibitor. AChE-IN-97 exhibits AChE and BChE inhibitory activity through molecular docking. AChE-IN-97 can be used for research on neurological conditions .

HY-181851

AChE-IN-109	Cholinesterase (ChE)	Neurological Disease
AChE-IN-109 is a potent mixed-type cholinesterase inhibitor with significantly stronger inhibitory activity against *AChE* than *BChE. AChE-IN-109 has IC₅₀* values of 0.55 μM and 12.45 μM against AChE and BChE, respectively. AChE-IN-109 inhibits cholinesterases through a mixed-type mechanism, binds to both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. AChE-IN-109 can be used for the study of Alzheimer’s disease (AD) .

HY-N16715

Monardic acid A	Cholinesterase (ChE)	Neurological Disease
Monardic acid A is a selective inhibitor of *AChE, with an IC₅₀* of 53.1 μM against AChE from electric eel. Monardic acid A shows weak inhibitory activity against human erythrocyte AChE (IC₅₀ >100 μM) and has no significant inhibitory effect on BChE. Monardic acid A reduces acetylcholine breakdown by inhibiting AChE activity, and also exhibits inhibitory activity against histamine release and hyaluronidase, thus exerting anti-inflammatory and neurotransmitter regulatory effects. Monardic acid A can be isolated from lungwort (Pulmonaria officinalis) and thyme (Thymus gobicus), and is mainly used in the development of anti-inflammatory drugs and drugs related to neurodegenerative diseases .

HY-182786

MAO-B-IN-56	Cholinesterase (ChE) Monoamine Oxidase Beta-secretase COX Amyloid-β	Neurological Disease
MAO-B-IN-56 is a multi-target-directed ligand with *AChE, BChE, MAO-B, and BACE1* inhibitory activity, with IC₅₀ values of 0.35 μM, 3.22 μM, 0.14 μM, and 3.85 μM respectively, and shows selectivity for *AChE* over *BChE* and MAO-B over MAO-A.MAO-B-IN-56 reduces amyloid-beta production, reduces paw edema, improves spatial memory, and enhances Alzheimer's disease hallmarks and associated histopathological alterations.MAO-B-IN-56 can be used for the research of alzheimer's disease .

HY-179621

EQ-04	Cholinesterase (ChE) Amyloid-β	Neurological Disease
EQ-04 is a highly selective positive allosteric modulator (PAM) of α7 nAChR. EQ-04 has no direct inhibitory activity on AChE and BChE. EQ-04 inhibits Aβ aggregation. EQ-04 has safe cytotoxicity and potent neuroprotective activity. EQ-04 can be used for the study of Alzheimer's disease.

HY-N9731

6-O-p-Hydroxybenzoylglutinoside	NF-κB	Others
6-O-p-Hydroxybenzoylglutinoside acts as a selective NF-κB inhibitor that suppresses the transcriptional activity of TNF-α-activated NF-κB (IC₅₀=52.78 μM). 6-O-p-Hydroxybenzoylglutinoside shows no significant inhibitory activity against sEH, *AChE, or BChE. 6-O-p-Hydroxybenzoylglutinoside is a caged chlorinated iridoid glycoside identified from the seeds of Catalpa bungei* (Manchurian catalpa) .

HY-N19401

Vescalagin	Cholinesterase (ChE) Carbonic Anhydrase Glycosidase JNK p38 MAPK	Metabolic Disease Inflammation/Immunology
Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a K_i value of 5.87 nM against *AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK* to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties .

4-Amino-2-chloropyrimidine	Biochemical Assay Reagents
4-Amino-2-chloropyrimidine is a pyrimidine derivative. 4-Amino-2-chloropyrimidine is a competitive inhibitor for *AChE* (K_i = 0.18 μM) and *BChE* (K_i = 1.324 μM). 4-Amino-2-chloropyrimidine fits in the binding pocket of 4BDS. 4-Amino-2-chloropyrimidine has high inhibitory activity on GST enzyme activity (IC₅₀ = 0.037 μM, K_i = 0.047 μM) in vitro .

Pteryxin 1 Publications Verification (+)-Pteryxin	Coumarins Phenylpropanoids Umbelliferae Plants Achillea atrata L. Source Classification	Cholinesterase (ChE) NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS) Nuclear Factor of activated T Cells (NFAT) p38 MAPK
Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a *BChE* inhibitor (IC₅₀=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca ²⁺-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease .

Sophoflavescenol	Flavonols Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification Cancer	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.

Magnotriol B	Magnoliaceae Houpoea officinalis (Rehder & E. H. Wilson) N. H. Xia & C. Y. Wu Phenols Polyphenols Plants Source Classification	Cholinesterase (ChE)
Magnotriol B is a cholinesterase inhibitor with IC₅₀ values of 12.63 nM and 14.5 nM against *AChE* and *BChE, respectively. Magnotriol B also exhibits significant NO inhibitory* activity with an IC₅₀ of 2.02 μM. Magnotriol B can be used in the research of neurodegenerative and inflammatory diseases .

Decaffeoylacteoside Decaffeoylverbascoside; Verbasoside	Labiatae Phenols Polyphenols Plants Source Classification Ambrosia hispida	Monoamine Oxidase Cholinesterase (ChE)
Decaffeoylacteoside is an inhibitor of AChE/BChE/LOX with moderate activity .

Monardic acid A	Structural Classification Lignans Phenylpropanoids Plants Pulmonaria officinalis L. Boraginaceae Source Classification	Cholinesterase (ChE)
Monardic acid A is a selective inhibitor of *AChE, with an IC₅₀* of 53.1 μM against AChE from electric eel. Monardic acid A shows weak inhibitory activity against human erythrocyte AChE (IC₅₀ >100 μM) and has no significant inhibitory effect on BChE. Monardic acid A reduces acetylcholine breakdown by inhibiting AChE activity, and also exhibits inhibitory activity against histamine release and hyaluronidase, thus exerting anti-inflammatory and neurotransmitter regulatory effects. Monardic acid A can be isolated from lungwort (Pulmonaria officinalis) and thyme (Thymus gobicus), and is mainly used in the development of anti-inflammatory drugs and drugs related to neurodegenerative diseases .

6-O-p-Hydroxybenzoylglutinoside	Structural Classification Catalpa bungei C. A. Mey. Phenols Bignoniaceae Plants Source Classification	NF-κB
6-O-p-Hydroxybenzoylglutinoside acts as a selective NF-κB inhibitor that suppresses the transcriptional activity of TNF-α-activated NF-κB (IC₅₀=52.78 μM). 6-O-p-Hydroxybenzoylglutinoside shows no significant inhibitory activity against sEH, *AChE, or BChE. 6-O-p-Hydroxybenzoylglutinoside is a caged chlorinated iridoid glycoside identified from the seeds of Catalpa bungei* (Manchurian catalpa) .

Vescalagin	Structural Classification Phenols Polyphenols Myrciaria dubia (Kunth) McVaugh Myrtaceae Plants Source Classification	Cholinesterase (ChE) Carbonic Anhydrase Glycosidase JNK p38 MAPK
Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a K_i value of 5.87 nM against *AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK* to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties .

Demande en ligne

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Civilité			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse e-mail *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarques